Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11159) 11159
Publication (679) 679
Book Review (208) 208
Book Chapter (51) 51
Conference Proceeding (20) 20
Dissertation (6) 6
Magazine Article (5) 5
Data Set (2) 2
Government Document (1) 1
Presentation (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
tolerability (10433) 10433
humans (7278) 7278
index medicus (4779) 4779
female (4627) 4627
male (4615) 4615
efficacy (4580) 4580
adult (3436) 3436
middle aged (3394) 3394
safety (3068) 3068
pharmacology & pharmacy (3051) 3051
treatment outcome (2446) 2446
aged (2409) 2409
double-blind (2381) 2381
pharmacokinetics (1682) 1682
adolescent (1550) 1550
clinical neurology (1541) 1541
double-blind method (1464) 1464
psychiatry (1333) 1333
drug therapy (1150) 1150
young adult (1013) 1013
dose-response relationship, drug (1007) 1007
care and treatment (877) 877
medicine & public health (846) 846
analysis (820) 820
medicine, general & internal (813) 813
therapy (803) 803
aged, 80 and over (781) 781
clinical trials (753) 753
child (750) 750
internal medicine (739) 739
drug therapy, combination (732) 732
neurosciences (717) 717
animals (714) 714
children (682) 682
trial (677) 677
prospective studies (674) 674
drug administration schedule (643) 643
management (625) 625
randomized controlled trials as topic (619) 619
research (618) 618
multicenter (609) 609
epilepsy (595) 595
schizophrenia (573) 573
pharmacodynamics (567) 567
time factors (556) 556
administration, oral (545) 545
dosage and administration (542) 542
retrospective studies (533) 533
placebo (531) 531
pharmacology/toxicology (527) 527
pharmacotherapy (501) 501
medicine, research & experimental (498) 498
immunology (494) 494
health aspects (490) 490
follow-up studies (488) 488
hypertension (474) 474
pharmacology (473) 473
quality of life (464) 464
oncology (447) 447
urology & nephrology (431) 431
metaanalysis (423) 423
anticonvulsants - therapeutic use (418) 418
risk factors (413) 413
open-label (410) 410
drugs (396) 396
quality-of-life (396) 396
child, preschool (394) 394
pediatrics (388) 388
pain (386) 386
neurology (385) 385
infectious diseases (380) 380
toxicology (370) 370
antipsychotic agents - therapeutic use (369) 369
cross-over studies (369) 369
placebo-controlled trial (365) 365
prevalence (363) 363
studies (363) 363
cardiac & cardiovascular systems (357) 357
severity of illness index (352) 352
patients (351) 351
medical research (348) 348
adults (343) 343
seizures (343) 343
clinical trials as topic (339) 339
antiepileptic drugs (338) 338
hypertension - drug therapy (332) 332
antipsychotic agents - adverse effects (331) 331
depression (330) 330
prevention (329) 329
antidepressants (325) 325
drug dosages (324) 324
risk (317) 317
migraine (316) 316
drug interactions (314) 314
complications and side effects (311) 311
usage (308) 308
monotherapy (301) 301
schizophrenia - drug therapy (299) 299
area under curve (287) 287
combination (282) 282
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10322) 10322
German (329) 329
Spanish (160) 160
Russian (142) 142
French (111) 111
Italian (70) 70
Polish (20) 20
Portuguese (20) 20
Turkish (19) 19
Czech (14) 14
Japanese (13) 13
Korean (8) 8
Hungarian (5) 5
Chinese (1) 1
Lithuanian (1) 1
Persian (1) 1
Serbian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Unexpectedly low rates of neuropsychiatric adverse effects associated with mefloquine repurposed for the treatment of glioblastoma
by Nevin, Remington L
Cancer, ISSN 0008-543X, 04/2019, Volume 125, Issue 8, pp. 1384 - 1385
ONCOLOGY | TOLERABILITY | Mefloquine | Glioblastoma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Single-And multiple-dose pharmacokinetics and tolerability of a paroxetine controlledrelease tablet in healthy Chinese subjects
by Chen, Rui and Shen, Kai and Hu, Pei
International Journal of Clinical Pharmacology and Therapeutics, ISSN 0946-1965, 2017, Volume 55, Issue 3, pp. 231 - 236
Paroxetine controlledrelease | Tolerability | Pharmacokinetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Is brivaracetam-induced elevation of carbamazepine-epoxide levels common and clinically relevant? — A case series
by Steinhoff, Bernhard J and Bacher, Matthias and Blickhan, Marko and Bernedo, Viviane and Dietmann, Daniel and Intravooth, Tassanai and Kornmeier, Reinhold and Kurth, Christoph and Mahn, Patricia and Schneider, Matthias and Stockinger, Jakob and Staack, Anke M
Epilepsy Research, ISSN 0920-1211, 01/2020, Volume 159, p. 106236
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Efficacy and tolerability of almotriptan in adolescents: A randomized, double-blind, placebo-controlled trial: Research submission
by Linder, Steven L and Mathew, Ninan T and Cady, Roger K and Finlayson, Gary and Ishkanian, Gary and Lewis, Donald W
Headache, ISSN 0017-8748, 10/2008, Volume 48, Issue 9, pp. 1326 - 1336
Almotriptan | Migraine | Efficacy | Tolerability | Adolescents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of safety and tolerability in subgroups
by Harper, Julie C and Roberts, Wendy E and Zeichner, Joshua A and Guenin, Eric and Bhatt, Varsha and Pillai, Radhakrishnan
Journal of Dermatological Treatment, ISSN 0954-6634, 2019, pp. 1 - 8
Topical tretinoin's role in acne has been established through evidence-based guidelines. Cutaneous irritation and potential to cause or exacerbate... 
tretinoin | Acne | tolerability | polymeric emulsion
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text A randomized, double‐blind, placebo‐controlled, multicenter, parallel‐group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial‐onset seizures
by Klein, Pavel and Schiemann, Jimmy and Sperling, Michael R and Whitesides, John and Liang, Wei and Stalvey, Tracy and Brandt, Christian and Kwan, Patrick
Epilepsia, ISSN 0013-9580, 12/2015, Volume 56, Issue 12, pp. 1890 - 1898
Summary Objective Brivaracetam (BRV), a selective and high‐affinity synaptic vesicle protein 2A ligand, is in development as adjunctive treatment for... 
Safety/tolerability | Partial‐onset seizures | Phase 3 | Efficacy | Focal epilepsy | Brivaracetam | Partial-onset seizures | CONTROLLED-TRIAL | PHASE-III | SYNAPTIC VESICLE PROTEIN | CLINICAL NEUROLOGY | SV2A | tolerability | Safety | LIGAND | BINDING | Pyrrolidinones - adverse effects | Anticonvulsants - adverse effects | Double-Blind Method | Epilepsies, Partial - drug therapy | Humans | Pyrrolidinones - therapeutic use | Anticonvulsants - therapeutic use | Adult | Female | Male | Treatment Outcome | Drugs | Medical research | Anticonvulsants | Epilepsy | Medicine, Experimental | Adults | Seizures (Medicine) | Confidence intervals
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Mycophenolic acid‐induced onychomadesis: An easily ignorable adverse effect in patients with rheumatic diseases
by Feng, Chi‐Wei and Chen, Hsiang‐Cheng and Lu, Chun‐Chi
International Journal of Rheumatic Diseases, ISSN 1756-1841, 04/2019, Volume 22, Issue 4, pp. 753 - 755
NAIL | THERAPY | RHEUMATOLOGY | TOLERABILITY | MOFETIL
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: A phase III randomized, double‐blind, placebo‐controlled trial
by Biton, Victor and Berkovic, Samuel F and Abou‐Khalil, Bassel and Sperling, Michael R and Johnson, Martin E and Lu, Sarah
Epilepsia, ISSN 0013-9580, 01/2014, Volume 55, Issue 1, pp. 57 - 66
Summary Purpose Brivaracetam (BRV) is a novel high‐affinity synaptic vesicle protein 2A ligand currently being investigated for the treatment of epilepsy. The... 
Safety/tolerability | Phase III | Efficacy | Brivaracetam | Partial epilepsy | CLINICAL NEUROLOGY | PARTIAL-ONSET SEIZURES | LACOSAMIDE | CNS PHARMACODYNAMICS | PHARMACOKINETICS | UCB-34714 | tolerability | Safety | PERAMPANEL | ADVERSE EVENT PROFILE | Double-Blind Method | Epilepsies, Partial - drug therapy | Humans | Middle Aged | Pyrrolidinones - therapeutic use | Anticonvulsants - therapeutic use | Anticonvulsants - administration & dosage | Male | Treatment Outcome | Pyrrolidinones - administration & dosage | Young Adult | Adolescent | Adult | Female | Aged | Drug Therapy, Combination | Analysis | Epilepsy | Electrocardiogram | Clinical trials | Electrocardiography | Urinary tract infections | Adults | Seizures (Medicine) | Drug therapy | Antiepileptic agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study
by Tassorelli, Cristina and Grazzi, Licia and de Tommaso, Marina and Pierangeli, Giulia and Martelletti, Paolo and Rainero, Innocenzo and Dorlas, Stefanie and Geppetti, Pierangelo and Ambrosini, Anna and Sarchielli, Paola and Liebler, Eric and Barbanti, Piero and PRESTO Study Grp and PRESTO Study Group and On behalf of the PRESTO Study Group
Neurology, ISSN 0028-3878, 07/2018, Volume 91, Issue 4, pp. e364 - e373
OBJECTIVETo evaluate the efficacy, safety, and tolerability of noninvasive vagus nerve stimulation (nVNS; gammaCore; electroCore, LLC, Basking Ridge, NJ) for... 
CONTROLLED-TRIAL | DICLOFENAC POTASSIUM | TRIPTANS SEROTONIN | EFFICACY | HEADACHE | 5-HT1B/1D AGONISTS | TOLERABILITY | DOUBLE-BLIND | OPEN-LABEL | PREVENTION AMPP | CLINICAL NEUROLOGY | 101 | 321 | 222 | 302
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open‐label extension of phase III randomized trials: Study 307
by Krauss, Gregory L and Perucca, Emilio and Kwan, Patrick and Ben‐Menachem, Elinor and Wang, Xue‐Feng and Shih, Jerry J and Patten, Anna and Yang, Haichen and Williams, Betsy and Laurenza, Antonio and Institute of Neuroscience and Physiology and Sahlgrenska akademin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy and Institutionen för neurovetenskap och fysiologi
Epilepsia, ISSN 0013-9580, 04/2018, Volume 59, Issue 4, pp. 866 - 876
Summary Objective To evaluate long‐term safety/tolerability and seizure outcomes in patients with focal seizures treated with adjunctive perampanel in the... 
focal seizures | perampanel | antiepileptic drugs | long‐term safety/tolerability | secondarily generalized seizures | long-term safety/tolerability | tolerability | RECEPTOR ANTAGONIST | ADVERSE EVENTS | CLINICAL NEUROLOGY | long-term safety | PARTIAL-ONSET SEIZURES | Epilepsies, Partial - diagnosis | Double-Blind Method | Drug Administration Schedule | Follow-Up Studies | Epilepsies, Partial - drug therapy | Humans | Dizziness - chemically induced | Seizures - drug therapy | Anticonvulsants - administration & dosage | Seizures - diagnosis | Treatment Outcome | Pyridones - administration & dosage | Anticonvulsants - adverse effects | Time Factors | Female | Drug Therapy, Combination | Headache - chemically induced | Pyridones - adverse effects | Drugs | Complications and side effects | Care and treatment | Analysis | Patient outcomes | Epilepsy | Product development | Seizures (Medicine) | Convulsions & seizures | Clinical trials | Fatigue | Safety | Antiepileptic agents | Patients | Seizures | Neurologi | Neurology | Neurosciences | Neurovetenskaper
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: Results from a double‐blind, randomized, placebo‐controlled trial
by Ryvlin, Philippe and Werhahn, Konrad J and Blaszczyk, Barbara and Johnson, Martin E and Lu, Sarah
Epilepsia, ISSN 0013-9580, 01/2014, Volume 55, Issue 1, pp. 47 - 56
Summary Purpose Brivaracetam (BRV) is a novel high‐affinity synaptic vesicle protein 2A ligand in clinical development for the treatment of epilepsy. This... 
Safety/tolerability | Phase III | Efficacy | Focal epilepsy | Brivaracetam | SV2A LIGAND | SYNAPTIC VESICLE PROTEIN | CLINICAL NEUROLOGY | PARTIAL-ONSET SEIZURES | CNS PHARMACODYNAMICS | PHARMACOKINETICS | tolerability | Safety | BINDING | ADVERSE EVENT PROFILE | Double-Blind Method | Epilepsies, Partial - drug therapy | Humans | Middle Aged | Pyrrolidinones - therapeutic use | Anticonvulsants - therapeutic use | Anticonvulsants - administration & dosage | Male | Treatment Outcome | Pyrrolidinones - administration & dosage | Young Adult | Adolescent | Adult | Female | Aged | Drug Therapy, Combination | Clinical trials | Anticonvulsants | Adults | Seizures (Medicine) | Analysis | Epilepsy | Antiepileptic agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text A Case Report of Immunosuppressant Medication‒Associated Polyarticular Tophaceous Gout Successfully Treated Using the Polyethylene Glycol‒Conjugated Uricase Enzyme Pegloticase
by Freyne, B
Transplantation Proceedings, ISSN 0041-1345, 12/2018, Volume 50, Issue 10, pp. 4099 - 4101
This case describes a female patient with polyarticular tophaceous gout who was given transplant immunosuppressant medications. The 36-year-old was treated for... 
SURGERY | IMMUNOLOGY | EFFICACY | TOLERABILITY | TRANSPLANTATION
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Efficacy of a new once-daily long-acting inhaled beta(2)-agonist indacaterol versus twice-daily formoterol in COPD
by Dahl, R and Chung, KF and Buhl, R and Magnussen, H and Nonikov, V and Jack, D and Bleasdale, P and Owen, R and Higgins, M and Kramer, B and INVOLVE INdacaterol Value COPD Lo
THORAX, ISSN 0040-6376, 06/2010, Volume 65, Issue 6, pp. 473 - 479
Background Indacaterol is a long-acting inhaled beta(2)-agonist (LABA) for the treatment of chronic obstructive pulmonary disease (COPD). In previous studies,... 
OBSTRUCTIVE PULMONARY-DISEASE | PLACEBO | CLINICAL-TRIAL | SAFETY | RESPIRATORY SYSTEM | DYSPNEA | TOLERABILITY | EXACERBATIONS | BROMIDE | INDEX | DRY POWDER
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine
by Goadsby, PJ and Wietecha, LA and Dennehy, EB and Kuca, B and Case, MG and Aurora, SK and Gaul, C
BRAIN, ISSN 0006-8950, 07/2019, Volume 142, Issue 7, pp. 1894 - 1904
Lasmiditan, a serotonin 5-HT1F receptor agonist, was effective for acute treatment of patients with migraine in a phase 3 double-blind randomized controlled... 
migraine | SAFETY | 5-HT1B/1D AGONISTS | PREVALENCE | NEUROSCIENCES | efficacy | CLINICAL NEUROLOGY | phase 3 | THERAPY | lasmiditan | TRIPTANS | PEOPLE | safety/tolerability | EPISODIC MIGRAINE | Clinical Trial | Editor's Choice | safety | tolerability
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Synergistic effects and mechanisms of impressic acid or acankoreanogein in combination with docetaxel on prostate cancer
by Jiang, Sen and Zhang, Kun and He, Yan and Xu, Xuetao and Li, Dongli and Cheng, Shupeng and Zheng, Xi
RSC Advances, ISSN 2046-2069, 2018, Volume 8, Issue 5, pp. 2768 - 2776
Prostate cancer (PCa) is a common cancer among males and a leading cause of cancer deaths. Docetaxel (DOC) was recommended in guidelines as the first... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Do Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics?
by Bai, Yuanhan and Chen, Guanjie and Yang, Haichen and Gao, Keming
Journal of Affective Disorders, ISSN 0165-0327, 01/2020, Volume 261, pp. 259 - 270
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Cannabis-Based Drugs Expert Consensus against systematic Reviews
by Schmelz, M and Hauser, W and Hoch, E and Petzke, F and Sommer, C
SCHMERZ, ISSN 0932-433X, 04/2019, Volume 33, Issue 2, pp. 97 - 98
EFFICACY | SAFETY | TOLERABILITY | ANESTHESIOLOGY | CLINICAL NEUROLOGY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Safety and feasibility of treatment simplification to atazanavir/ ritonavir1lamivudine in hiv-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors1atazanavir/ ritonavir with virological suppression (atazanavir and lamivudine for treatment simplification, atlas pilot study)
by Giambenedetto, Simona Di and Fabbiani, Massimiliano and Colafigli, Manuela and Ciccarelli, Nicoletta and Farina, Salvatore and Sidella, Letizia and D'Avino, Alessandro and Mondi, Annalisa and Cingolani, Antonella and Tamburrini, Enrica and Murri, Rita and Navarra, Pierluigi and Cauda, Roberto and Luca, Andrea De
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 06/2013, Volume 68, Issue 6, pp. 1364 - 1372
Dual therapy | Long-term tolerability | Switch | Combined antiretroviral therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text Hybrid Nanostructured Films for Topical Administration of Simvastatin as Coadjuvant Treatment of Melanoma
by Barone, Antonella and Mendes, Maria and Cabral, Célia and Mare, Rosario and Paolino, Donatella and Vitorino, Carla
Journal of Pharmaceutical Sciences, ISSN 0022-3549, 10/2019, Volume 108, Issue 10, pp. 3396 - 3407
This work aims at (1) assessing the potential of repurposing simvastatin (SV) to support the most common therapies against melanoma and (2) developing an... 
topical film | simvastatin | melanoma | nanostructured lipid carriers | topical treatment | tolerability
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
by Robson, M.E and Tung, N and Conte, P and Im, S-A and Senkus, E and Xu, B and Masuda, N and Delaloge, S and Li, W and Armstrong, A and Wu, W and Goessl, C and Runswick, S and Domchek, S.M
Annals of oncology : official journal of the European Society for Medical Oncology, ISSN 0923-7534, 04/2019, Volume 30, Issue 4, pp. 558 - 566
Background: In the OlympiAD study, olaparib was shown to improve progression-free survival compared with chemotherapy treatment of physician's choice (TPC) in... 
germline BRCA mutation | overall survival | breast cancer | olaparib | PARP inhibitor | tolerability | ONCOLOGY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.